Although CD38 is not highly expressed by osteoblasts [13], our results point towards an indirect effect of daratumumab inducing bone formation, which is mediated by both an anti-myeloma effect and a decrease in inhibitors of osteoblast activity. Here, CD38 is linked to plasma cell myeloma.